Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology
Published at: www.medicalnewstoday.com
-
Percutaneous valve repair – next battle among cardiovascular device companies?
October 4, 2009
By acquiring promising technology in the percutaneous valve arena, as well as enjoying an already established reputation among interventional cardiologists, Abbott will position itself as a major player in an emerging technology market, and become a comprehensive provider for interventional cardiology solutions.
-
The Logical Next Step for Abbott
September 15, 2009
With this acquisition Abbott establishes its position as a major player in the field of interventional cardiology and treatment of structural heart disease.The field of structural heart disease therapy is the fastest growing area of interventional cardiology and Abbott is getting in at the ground floor.In addition to Edwards and Medtronic which have aortic valve stents in the pipeline, the Evalve system is the most advanced valve repair system.
-
Abbot will benefit in long run with acquisition of Evalve.
September 15, 2009
The acquisition will definitely have a significantly beneficial effect on the market standing as well as product portfolio of Abbot. Even though at the present time this technique developed by Evalve Inc. is useful only for a very small subset of patients, eventually Abbott can develop it further to extend it to a bigger group and therefore in the long run it will be able to win a bigger market share.
-
September 14, 2009
Good ideas and good products are better improved and marketed as a products of a large company, but....
-
Abbott to become a comprehensive structural heart disease provider
September 14, 2009
With the acquisition of Evalve, Abbott will position itself on the lead for structural heart disease.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.